Serological analysis of human renal cell carcinoma

Authors

  • Gerard Devitt,

    1. Department of Tumor Progression and Immune Defence, German Cancer Research Center, 69120 Heidelberg, Germany
    2. Department of Applied Genetics, University of Karlsruhe, 76128 Karlsruhe, Germany
    Search for more papers by this author
  • Christiane Meyer,

    1. Department of Tumor Progression and Immune Defence, German Cancer Research Center, 69120 Heidelberg, Germany
    Search for more papers by this author
  • Nicole Wiedemann,

    1. Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany
    Search for more papers by this author
  • Stefan Eichmüller,

    1. Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany
    Search for more papers by this author
  • Annette Kopp-Schneider,

    1. Department of Statistics, German Cancer Research Center, 69120 Heidelberg, Germany
    Search for more papers by this author
  • Axel Haferkamp,

    1. Department of Urology, University Hospital, Ruperto Carola University, 69115 Heidelberg, Germany
    Search for more papers by this author
  • Richard Hautmann,

    1. Department of Urology, University Hospital, University of Ulm, 89075 Ulm, Germany
    Search for more papers by this author
  • Margot Zöller

    Corresponding author
    1. Department of Tumor Progression and Immune Defence, German Cancer Research Center, 69120 Heidelberg, Germany
    2. Department of Applied Genetics, University of Karlsruhe, 76128 Karlsruhe, Germany
    Current affiliation:
    1. Department of Infection and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany
    • Department of Infection and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany
    Search for more papers by this author
    • Fax: +6221-424760


Abstract

Serological analysis of cDNA expression libraries (SEREX) has proven to be a useful technique in the quest to elucidate the repertoire of immunogenic gene products in human cancer. We have applied the SEREX method to human renal cell carcinoma (RCC) in order to identify associated immunogenic gene products. cDNA expression libraries were prepared from a RCC tumor, a RCC cell line and human testis. The 3 libraries were screened with sera from 35 RCC patients and 15 healthy controls. Approximately 4.5 × 106 phage plaques were screened resulting in 234 positive clones, which corresponded to 74 different gene products. The seroreactivity toward 49 of these antigens was assessed. Seroreactivity to 21 (43%) of the antigens was similar in RCC patients and healthy controls, 9 antigens (18%) elicited antibodies more frequently and 19 antigens (39%) solely in RCC patients. In the reverse setting, reactivity of RCC patients' sera was tested against a panel of 44 previously identified “tumor-associated” antigens via the SADA (serum antibody detection array) method; 6 antigens reacted with RCC patients' and healthy donors' sera, 8 were reactive only with RCC patients' sera. From the 27 antigens identified by SEREX and SADA, which did not react with sera from healthy controls, 10 antigens reacted with a significant proportion of RCC patients' sera and 77% of RCC patients' sera reacted at least with one of these antigens. Sera from patients with non-malignant renal diseases or an autoimmune disease did not react with these 10 antigens. © 2005 Wiley-Liss, Inc.

Ancillary